We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pacific Biosciences (PACB) Q3 Loss Wider Than Estimates
Read MoreHide Full Article
Pacific Biosciences of California, Inc. (PACB - Free Report) incurred third-quarter 2019 adjusted loss of 19 cents per share, wider than the Zacks Consensus Estimate of a loss of 15 cents. The company had reported a loss of 19 cents a year ago.
Revenues totaled $21.9 million, which missed the Zacks Consensus Estimate by 21.8%. Revenues improved 20.7% from the year-ago quarter’s tally.
Segmental Analysis
Product Revenue: At this segment, revenues amounted to $18.5 million, up 22% from the prior-year quarter’s tally.
Pacific Biosciences of California, Inc. Price, Consensus and EPS Surprise
Service and Other Revenue: At this segment, revenues came in at $3.4 million, up 14% year over year.
Margin Analysis
Gross profit in the third quarter of 2019 was $6.9 million, up a significant 116.6% on a year-over-year basis. Gross margin was 31.5% of total revenues, improving significantly from the year-ago quarter’s 17.6%.
Research and Development expenses increased 4.2% to $15 million in the quarter. Further, sales, general and administrative expenses rose 48.6% to $20.1 million.
Operating expenses totaled $35 million, up 25.7% year over year.
About the Illumina & Pacific Biosciences Merger
Illumina (ILMN - Free Report) has confirmed its merger with Pacific Biosciences. Per management, the total value of the deal is approximately $1.2 billion.
For the three months ended Sep 30, 2019, Pacific Biosciences recognized approximately $3.6 million in operating expenses pertaining to the merger.
Zacks Rank
Pacific Biosciences carries a Zacks Rank #3 (Hold).
NuVasive’s third-quarter 2019 adjusted EPS of 59 cents beat the consensus estimate by 9.3%. Its revenues of $290.8 million outpaced the consensus mark by 2.4%.
Thermo Fisher delivered third-quarter 2019 adjusted EPS of $2.94, beating the Zacks Consensus Estimate by 2.1%. Its revenues of $6.27 billion exceeded the Zacks Consensus Estimate by 1.3%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Pacific Biosciences (PACB) Q3 Loss Wider Than Estimates
Pacific Biosciences of California, Inc. (PACB - Free Report) incurred third-quarter 2019 adjusted loss of 19 cents per share, wider than the Zacks Consensus Estimate of a loss of 15 cents. The company had reported a loss of 19 cents a year ago.
Revenues totaled $21.9 million, which missed the Zacks Consensus Estimate by 21.8%. Revenues improved 20.7% from the year-ago quarter’s tally.
Segmental Analysis
Product Revenue: At this segment, revenues amounted to $18.5 million, up 22% from the prior-year quarter’s tally.
Pacific Biosciences of California, Inc. Price, Consensus and EPS Surprise
Pacific Biosciences of California, Inc. price-consensus-eps-surprise-chart | Pacific Biosciences of California, Inc. Quote
Service and Other Revenue: At this segment, revenues came in at $3.4 million, up 14% year over year.
Margin Analysis
Gross profit in the third quarter of 2019 was $6.9 million, up a significant 116.6% on a year-over-year basis. Gross margin was 31.5% of total revenues, improving significantly from the year-ago quarter’s 17.6%.
Research and Development expenses increased 4.2% to $15 million in the quarter. Further, sales, general and administrative expenses rose 48.6% to $20.1 million.
Operating expenses totaled $35 million, up 25.7% year over year.
About the Illumina & Pacific Biosciences Merger
Illumina (ILMN - Free Report) has confirmed its merger with Pacific Biosciences. Per management, the total value of the deal is approximately $1.2 billion.
For the three months ended Sep 30, 2019, Pacific Biosciences recognized approximately $3.6 million in operating expenses pertaining to the merger.
Zacks Rank
Pacific Biosciences carries a Zacks Rank #3 (Hold).
Earnings of MedTech Majors at a Glance
Some better-ranked companies which posted solid results this earning season are NuVasive, Inc and Thermo Fisher Scientific Inc (TMO - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
NuVasive’s third-quarter 2019 adjusted EPS of 59 cents beat the consensus estimate by 9.3%. Its revenues of $290.8 million outpaced the consensus mark by 2.4%.
Thermo Fisher delivered third-quarter 2019 adjusted EPS of $2.94, beating the Zacks Consensus Estimate by 2.1%. Its revenues of $6.27 billion exceeded the Zacks Consensus Estimate by 1.3%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>